Ignis Therapeutics (Suzhou) Co. Ltd. has synthesized new tetrahydroisoquinoline compounds acting as dopamine D1 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of apathy, Parkinson’s disease, Huntington’s disease, dystonia, Alzheimer’s disease, neuropathic pain, psychosis and sleep disorder and among others.

Prospect Therapeutics Inc. has patented new nitrogen-containing heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.

Chengdu Chipscreen Pharmaceutical Ltd. has divulged new 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors potentially useful for the treatment of obesity.

Zealand Pharma A/S has identified new interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis.

H. Lundbeck A/S has disclosed new orexin OX2 receptor agonists potentially useful for the treatment of type 1 and type 2 narcolepsy.

Shanghai Huilun Pharmaceutical Co. Ltd. has identified new angiotensin AT2 receptor antagonists potentially useful for the treatment of neuropathic pain.

Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new platelet adhesion inhibitors reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.

A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.

Wuhan Createrna Science and Technology Co. Ltd. has synthesized new cyclobutenedione compounds acting as C-C chemokine receptor type 6 (CCR6) antagonists potentially useful for the treatment of inflammatory bowel disease, allergy, dry eye, psoriasis, rheumatoid arthritis and multiple sclerosis.

Shenzhen Salubris Pharmaceuticals Co. Ltd. has disclosed new dual proprotein convertase subtilisin/kexin-type 9 (PCSK9) and lipoprotein(a) (Lp[a])-targeting agents potentially useful for the treatment of hypercholesterolemia.